Central Nervous System Aging Reversal With AAV Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aging in the central nervous system is primarily driven by the loss of epigenetic information, leading to neuronal plasticity loss and cognitive decline, with existing treatments failing to address the underlying cellular causes.
Innovation Solution
Precise expression of OCT4, SOX2, and KLF4 transcription factors, delivered via adeno-associated virus (AAV) vectors, permeates the blood-brain barrier to reverse aging and rejuvenate brain cells without exogenous c-Myc expression, promoting tissue regeneration and improving neuronal function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Yamanaka factors (OCT4, SOX2, c-Myc, and KLF4) are expressed to induce pluripotency and reverse DNA methylation clock, then cellular youthfulness and regenerative capacity are restored, but teratomas and acute toxicities are induced that can kill the animal
Solution Approach 1:
The patent removes c-Myc from the traditional Yamanaka factor combination, using only OCT4, SOX2, and KLF4. This extraction of the most harmful component eliminates teratoma formation and acute toxicity while preserving the ability to reverse DNA methylation and restore cellular youthfulness in the central nervous system
Solution Approach 2:
The patent uses cell-type-specific promoters (Synapsin-1 for neurons, GFAP for astrocytes, OLIG2 for oligodendrocytes) to drive expression of the transcription factors only in specific CNS cell types. This localized expression prevents systemic effects and teratoma formation while achieving rejuvenation in target cells
2Reliability
If epigenetic reprogramming is performed to reverse aging, then neuronal plasticity and cognitive function are improved, but the complexity of the reprogramming system increases
Solution Approach 1:
The patent uses a universal set of three transcription factors (OCT4, SOX2, KLF4) that can reprogram multiple different cell types in the CNS (neurons, astrocytes, oligodendrocytes) through cell-type-specific promoters. This multi-functional approach simplifies the system compared to using different factor combinations for each cell type
Solution Approach 2:
The patent employs AAV (adeno-associated virus) vectors as intermediaries to deliver the transcription factor genes into CNS cells. The viral vectors efficiently transduce neurons and glial cells, enabling epigenetic reprogramming without requiring complex transfection protocols or direct injection methods
3Ease of operation
If traditional aging treatments target proteins to modulate neurotransmitter activity, then symptomatic relief is achieved, but the underlying cellular causes of aging are not addressed
Solution Approach 1:
The patent performs preliminary action by reversing epigenetic changes and restoring cellular youthfulness before neurological symptoms manifest or worsen. By targeting the root cause (epigenetic aging) rather than downstream effects (neurotransmitter dysfunction), the treatment prevents disease progression rather than merely managing symptoms
Solution Approach 2:
The patent replaces the mechanical/pharmacological approach of modulating neurotransmitter receptors with a biological approach of reprogramming gene expression through transcription factors. This substitution targets the fundamental cellular machinery (epigenome) rather than downstream signaling pathways
Data Source
AI summary
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.